Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Genmab A/S
Accelerated approval of Tivdak in recurrent or metastatic cervical cancer brings Seagen’s fourth cancer therapy and third antibody-drug conjugate to market. Merck is advancing Keytruda in r/mCC as well.
In addition to securing a key position in first-line disease, Keytruda has potential to expand its presence in later lines with combination data from Seagen/Genmab’s Tivdak.
At ESMO, data showed objective response benefit in combination with carboplatin in first-line therapy, and with Keytruda in second- or third-line treatment. The antibody-drug conjugate obtained US approval on 20 September as monotherapy.
Janssen’s Mark Wildgust explained how the Johnson & Johnson subsidiary is pushing forward with novel therapeutics and combination regimens with the goal of eliminating myeloma in the first line.
- Large Molecule